HHlevo-M Kid Tablet DT is a pediatric formulation combining Levocetirizine (2.5 mg) and Montelukast (4 mg) designed for the management of allergic conditions in children. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, effectively alleviating symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, thereby reducing airway inflammation, bronchoconstriction, and mucus production commonly associated with asthma and allergic rhinitis. The dual-action mechanism of HHlevo-M Kid Tablet DT provides comprehensive symptomatic relief by targeting both histamine-mediated and leukotriene-mediated pathways. The tablet is formulated as a dispersible tablet (DT) to facilitate ease of administration and improve compliance in pediatric patients who may have difficulty swallowing conventional tablets. HHlevo-M Kid Tablet DT is indicated for the treatment of allergic rhinitis, chronic urticaria, and mild to moderate asthma in children. It should be used under medical supervision, with dosage adjustments based on age and clinical response. Common side effects may include headache, somnolence, and gastrointestinal disturbances, though the combination is generally well tolerated. Caution is advised in patients with hepatic or renal impairment.